Undisclosed Rare Disease Program(s)

About Base4

Base4 Biotechnology is a private, preclinical-stage company pioneering a structure-based approach to discover small molecules that target RNA, a challenging but high-potential therapeutic modality. Its core asset is the VERITAS Platform, an AI and quantum biophysics-enhanced platform designed to resolve the dynamic atomic structures of RNA and identify druggable sites. Led by a seasoned team with prior biotech founding and exit success, the company is advancing internal programs while seeking strategic partnerships to accelerate drug development in neurodegenerative diseases, oncology, and rare conditions.

Therapeutic Areas

Other Rare Diseases Drugs